This event is made possible by sponsorship from organisations including pharmaceutical companies, med tech companies and service providers none of which have influenced the event content or the choice of speakers. Sessions delivered with input from these organisations will be marked as such on the programme.
You can also see our full list of exhibitors.
Bronze sponsor
MEDICE UK is a family-owned European pharmaceutical company, proud to be a market leader in the treatment of ADHD. MEDICE UK is here to support UK healthcare professionals and their patients, with the supply of ADHD treatments.
Come & join the conversation around ADHD at the MEDICE UK stand.
Rare Disease Hub sponsors
Especially for 2025, our Rare Disease Hub takes place in the Exhibition Hall during breaks. It will provide up-to-date insights into early diagnosis, emerging therapies and holistic care strategies in rare diseases in infants, children and young people. It is a collaboration between RCPCH, British Paediatric Surveillance Unit and expert clinicians, charities and commercial organisations that specialise in this area.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Kyowa Kirin International, "Commitment to Life" is at our core. With over 500 people focused on this purpose we've become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of unmet therapeutic needs.
Orchard Therapeutics, is dedicated to empowering life and inspiring new possibilities for people affected by certain rare inherited diseases. Through our mission to develop one-time, disease altering therapies for a range of devastating genetic conditions, we seek to have a lasting effect on children, families, caregivers, and society.